Clinical Trial Update: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the combination of BGB-290 with temozolomide in patients with IDH1/IDH2-mutant gliomas, including glioblastoma and various W…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Low-grade Glioma
• Malignant Glioma

Drugs mentioned

• BGB-290
• Temozolomide (Temozolomide)

Snippet

Sponsor: University of California, San Francisco | Conditions: Glioblastoma, IDH1 Gene Mutation | Phase 1 | Status: ACTIVE_NOT_RECRUITING